TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Degree of extensor lag at distal inter-phalangeal (DIP) joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Berg balance scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline mean velocity of centre of pressure during quiet stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline stride time variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Extremity Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Without Loss of Disease Activity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients meeting heart rate reduction criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of participants experiencing dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants experiencing clinical or laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: serum pharmacokinetics of DS-8895a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting a Solicited Local or Systemic Reaction Post-Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinuing Study Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Positive Platelet Response to MK-8723
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Antigen-presenting B Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of NCI CTCAE v 5.0 grade ≥3
Endpoint domain: Adverse events/effects
Primary endpoint: successful completion of curative surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Observed maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed time to maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent elimination half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S. pneumoniae carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Programme Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Monitoring of Adverse and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Monitoring for deviations from study protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in middle cerebral artery resistive index after treatment with rifaximin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in middle cerebral artery pulsatility index after treatment with rifaximin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in posterior cerebral artery resistive index after treatment with rifaximin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in posterior cerebral artery pulsatility index after treatment with rifaximin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Joint Space Width (JSW) in the Medial Tibiofemoral Knee Joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: WOMAC Pain Subscore in the Signal Knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: WOMAC Function Subscore in the Signal Knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Displacement of the laryngeal mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiothymic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Knee Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Hip Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Major catheter related infection
Endpoint domain: Adverse events/effects
Primary endpoint: Lower extremity muscle activation onset latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centre of pressure movement in standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBECD plasma and effluent concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: autonomic nervous function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major Adverse Cardiac and Cerebrovascular Ischemic Events (MACCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of Rotavirus Vaccine Strain in Stool Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AAA maximum diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AAA volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hamilton Rating Scale for Depression (HRSD) Improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the 'Weekly minutes of moderate- to-vigorous physical activity (MVPA)'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the 'Sitting time per week'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving HbA1c reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of MRPs experienced by study participants
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Graft Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of ABBC2 polymorphism (rs12762549)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SLC01B3 polymorphism (rs11045585)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomechanical analysis using 3D motion capture looking at kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography analysis of muscle co-contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NIHSS Scores from Baseline to 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in NIHSS Scores from Baseline to 4 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time till not soiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with abnormal safety and tolerability assessment parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Barkley side effects rating scale
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence of difficult intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of endotracheal tube sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical Failure Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of DOT Diary Mobile App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of Use of DOT Diary Mobile App
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence and Persistence of Use of DOT Diary
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: local pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Leflunomide + Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: KOOS subscale pain and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Respiratory Exacerbation Requiring Intravenous Antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participant recruitment and retention rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of women who have repeat screening mammogram
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Skeletal relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of hospitalization days related to diabetic foot ulcers
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proteolytic activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of participants coming for a HIV re-test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain severity and interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in sub spine impingement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postcancer fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sequelae pain after breast cancer surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Have Cystitis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Have Pyelonephritis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Human Immuno Deficiency Virus-1 (HIV-1) Infection Diagnosed Between Month 7 to Month 24 Post Enrollment
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Local Reactogenicity Signs and Symptoms After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unsolicited Adverse Events (AEs) for 30 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTHRC1 value in diagnosis of rheumatoid arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arithmetic mean E. coli count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of metastatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vitamin D levels in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Withdrawn From the Study Due to Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose When Compared to Day 61
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kappa of diagnostic consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients requiring invasive measures for postpartum hemorrhage control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total cost associated with postpartum hemorrhage management strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grade of Muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Histopathology Score of Sun Damaged Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Average Forced Expiratory Volume in 1 Second (FEV1) AUC0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in 24 Hour Average Pain Item Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal vaginal squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bloatedness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to achieve 50% decrease in direct bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Relief from abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ability to resume domestic activity independently
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in numeric pain score rating at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in numeric pain score rating with respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial biological profile of children with COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Initial immunological profile of children with COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics (PK) of GSK1120212
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net Promoter Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Electromyographic Activity of Sternocleidomastoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI-z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Enhanced Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of circulating Tregs expressing gut homing receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Treatment-emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Ottawa GRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of stone removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bacterial load and contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in number of Participants With Gastroesophageal Reflux Disease (GERD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of death of MNP patients who had COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Rate of serious coronavirus infection in different MNP patient subgroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of passages in intensive care with need for mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in the Chinese Medicine patient-reported-outcome scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Warters Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in discontinuing GI medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success in maintaining reduced doses of GI medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean PSV of Cavernosal Arteries Before Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean PSV of Cavernosal Arteries After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-24 Hours of Ropinirole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Adverse Events Across Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Total remission rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of bladder measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of BCCs pathologically clear of tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Attendance status to Information Class
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in Cerebral Perfusion Pressure (CPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wrinkle Severity Rating Scale (WSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: brain activity during oesophageal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Minimum plasma concentration of fomepizole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular risk perceived by patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiovascular risk assessed by physicians
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive global executive z score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: hemoglobin response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Days needed for complete re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Graft complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of all treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of unexpected treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Length of Progression-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in tear break up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Evidence of chronic obstructive pulmonary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjects With Treatment-emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects With Serious Adverse Event (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Vital Sign Values of Toxicity Grade 1 or Higher Postdose
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical healing of anoperineal fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Anxiety Stress Scales (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Perceived Stress Scale 4 (PSS-4)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SA burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social Phobia and Anxiety Inventory for Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of large for gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Degree of gait recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of ESR1 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: wheal size of immediate type skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Irradiance-dependent pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of safety in public transport
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Failure rates
Endpoint domain: Mortality/survival
Primary endpoint: Change in mean seated trough DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time until hematologic nadirs (WBC, ANC, platelets)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes